Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hereditary angioedema type 2 (HAE 2) is a form of hereditary angioedema characterized by acute edema in subcutaneous tissues, viscera and/or the upper airway.
Biomarker and diagnostic research for hereditary angioedema type 2 has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
3 clinical trials registered, 2 recruiting. Interventions under study include drug therapy. Pipeline includes 2 PHASE3, 1 PHASE2. Research is primarily industry-sponsored.
43 publications have been identified in PubMed for hereditary angioedema type 2. Research spans Epidemiology / Natural History (26%), Clinical Trial Publication (23%), and Review / Meta-Analysis (21%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 11 | 26% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 11:12 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Clinical study results | 10 | 23% |
Research summaries | 9 | 21% |
Patient case studies | 7 | 16% |
Testing and diagnosis research | 4 | 9% |
Laboratory research | 1 | 2% |
New treatment approaches | 1 | 2% |
Guan Z (2026). [PMID: 41560114](https://pubmed.ncbi.nlm.nih.gov/41560114/). *Medicine*. [Case Report / Case Series]
Maurer M (2026). [PMID: 41865747](https://pubmed.ncbi.nlm.nih.gov/41865747/). *Lancet Haematol*. [Clinical Trial Publication]
Aykan FS (2026). [PMID: 41814599](https://pubmed.ncbi.nlm.nih.gov/41814599/). *Allergol Immunopathol (Madr)*. [Epidemiology / Natural History]
Li X (2026). [PMID: 41578566](https://pubmed.ncbi.nlm.nih.gov/41578566/). *Medicine (Baltimore)*. [Case Report / Case Series]
Jones D (2026). [PMID: 41533199](https://pubmed.ncbi.nlm.nih.gov/41533199/). *Clin Exp Med*. [Epidemiology / Natural History]
Kural RF (2026). [PMID: 41742205](https://pubmed.ncbi.nlm.nih.gov/41742205/). *Orphanet J Rare Dis*. [Epidemiology / Natural History]
Aygören-Pürsün E (2026). [PMID: 41865746](https://pubmed.ncbi.nlm.nih.gov/41865746/). *Lancet Haematol*. [Clinical Trial Publication]
Ferrara AL (2025). [PMID: 38935036](https://pubmed.ncbi.nlm.nih.gov/38935036/). *Allergy*. [Basic Science / Preclinical]
Akten HS (2025). [PMID: 40380370](https://pubmed.ncbi.nlm.nih.gov/40380370/). *Allergy and asthma proceedings*. [Epidemiology / Natural History]
Gokmen NM (2025). [PMID: 40604794](https://pubmed.ncbi.nlm.nih.gov/40604794/). *BMC Oral Health*. [Epidemiology / Natural History]